Yu Cao

Qingdao University

H指数:21

被引数:1,229

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Presence of drug-drug interactions between esomeprazole and an ALK tyrosine kinase inhibitor (Dirozalkib)

esomeprazole与ALK酪氨酸激酶抑制剂(Dirozalkib)之间存在药物-药物相互作用

Cancer Chemotherapy and Pharmacology

IF2.3

2025-12-050

PRE

Bioequivalence Study of Tadalafil Oral Soluble Film and Tadalafil Tablet in Healthy Chinese Volunteers Under Fasting Conditions

空腹条件下他达拉非口服溶融薄膜与他达拉非片剂的生物等效性研究在中国健康志愿者中的比较

CTS-CLINICAL AND TRANSLATIONAL SCIENCE

IF2.8

2025-12-030

OAAI

Hepatic acetyl-CoA metabolism modulates neuroinflammation and depression susceptibility via acetate

肝脏乙酰辅酶A代谢通过乙酸调节神经炎症和抑郁易感性

Cell Metabolism

IF30.9

2025-09-230

PRE

Beyond the tumor: Enhancing pancreatic cancer therapy through glutamine metabolism and innovative drug delivery

超越肿瘤：通过谷氨酰胺代谢与创新药物递送提升胰腺癌疗法

cell communication and signaling

IF3.9

2025-07-090

Effects and the mechanism of pine pollen polysaccharides on diabetic wound healing in vitro and in vivo

松花粉多糖对糖尿病伤口愈合的效应及机制：体外与体内研究

Regenerative Therapy

IF3.5

2025-06-250

PREAI

Gut microbiome and metabolome profiles in renal allograft rejection from multiomics integration

肾移植排斥反应中肠道微生物组和代谢组特征的多组学整合分析

MSYSTEMS

IF4.6

2025-05-200

Hydrochlorothiazide disrupts DNA damage response to exacerbate skin photosensitivity

ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY

IF6.1

2024-11-010

OAAI

Usefulness of the Systemic Inflammation Response Index and the Systemic Immune Inflammation Index in Predicting Restenosis After Stent Implantation

全身炎症反应指数和全身免疫炎症指数在预测支架植入术后再狭窄中的作用

inflammation research

IF4.1

2024-07-012

Tunlametinib (HL-085) plus vemurafenib in patients with advanced BRAF V600-mutant solid tumors: an open-label, single-arm, multicenter, phase I study

hematology oncology

IF13.5

2024-06-121

OAAI

The Pharmacogenetic Variability Associated with the Pharmacokinetics and Pharmacodynamics of Rivaroxaban in Healthy Chinese Subjects: A National Multicenter Exploratory Study

CLINICAL THERAPEUTICS

IF3.6

2024-04-012

PRE

Primate Model Carrying LMNA Mutation Develops Dilated Cardiomyopathy

JACC-BASIC TO TRANSLATIONAL SCIENCE

IF7.2

2024-03-015

Safety and pharmacokinetic profiles of a humanized monoclonal antibody TQH2722 targeting interleukin 4 receptor alpha (IL-4Rα) in health adult subjects

BRITISH JOURNAL OF DERMATOLOGY

IF9.6

2024-02-071

PRE

Characteristic Profiling of Soluble Factors in the Cerebrospinal Fluid of Patients With Neurosyphilis

JOURNAL OF INFECTIOUS DISEASES

IF4.5

2024-01-172

PRE

Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study

ANNALS OF ONCOLOGY

IF65.4

2023-10-012

Protective effects and regulatory mechanisms of Shen-shuai-yi recipe on renal fibrosis in unilateral ureteral obstruction-induced mice

参衰益方对单侧输尿管梗阻小鼠肾纤维化的保护作用及调控机制

HELIYON

IF3.6

2023-07-011

OAAI

Pemigatinib in Chinese patients with advanced/metastatic or surgically unresectable cholangiocarcinoma Including FGFR2 fusion or rearrangement: Updated overall survival from an open-label, single-arm, multicenter Phase II study

CANCER RESEARCH

IF16.6

2023-04-141

PRE

Safety, pharmacokinetics, and pharmacodynamics of SHR7280, an oral gonadotropin-releasing hormone receptor antagonist, in healthy men: a randomized, double-blind, placebo-controlled phase 1 study

BMC MEDICINE

IF8.3

2023-04-030

OAAI

Circulating miR-320a-3p and miR-483-5p level associated with pharmacokinetic-pharmacodynamic profiles of rivaroxaban

HUMAN GENOMICS

IF4.3

2022-12-285

OAAI

Tetrahydrocurcumin improves lipopolysaccharide-induced myocardial dysfunction by inhibiting oxidative stress and inflammation via JNK/ERK signaling pathway regulation

PHYTOMEDICINE

IF8.3

2022-09-0133

OAAI

PCSK9 inhibitor recaticimab for hypercholesterolemia on stable statin dose: a randomized, double-blind, placebo-controlled phase 1b/2 study

BMC MEDICINE

IF8.3

2022-01-1816

OAAI

Yu Cao

个人简介

教育背景

工作经历

荣誉奖项

研究方向